Physician profile
Charles Sweet
NPI 1164568283
$39,277.46
in general payments reported to CMS, 2019-2025
49 companies · $2,432 in 2025
The $2,432 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $6,002 · 2021: $6,127 · 2022: $4,141 · 2023: $2,303 · 2024: $1,627 · 2025: $2,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,361.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14,896.82 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $4,765.94 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $3,011.02 | 2021-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $1,766.29 | 2019-2025 | Adzenys Xr-Odt |
| Alkermes, INC. | $1,605.83 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,308.94 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,155.96 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $994.53 | 2019-2025 | Rexulti |
| Tris Pharma INC | $909.41 | 2019-2025 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $895.64 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $794.96 | 2019-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $738.56 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $690.84 | 2020-2025 | Caplyta |
| Allergan, INC. | $655.65 | 2019-2020 | |
| Corium, LLC | $494.61 | 2022-2025 | Azstarys |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $477.20 | 2019-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $469.37 | 2019-2022 | |
| Axsome Therapeutics, INC. | $364.53 | 2022-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $352.66 | 2025 | Cobenfy, Breyanzi |
| Neurocrine Biosciences, INC. | $320.83 | 2019-2025 | Ingrezza |
| Bausch Health US, LLC | $290.30 | 2019-2025 | Aplenzin |
| Janssen Scientific Affairs, LLC | $257.37 | 2024-2025 | Spravato, Invega Trinza |
| Noven Pharmaceuticals, INC. | $244.17 | 2023-2024 | Xelstrym |
| Arbor Pharmaceuticals, INC. | $238.79 | 2019-2021 | |
| Eisai INC. | $225.79 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2020 | |
| Adlon Therapeutics L.P. | $144.83 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $141.28 | 2019-2025 | Relexxii |
| Sumitomo Pharma America, INC. | $129.26 | 2023 | |
| Avanir Pharmaceuticals, INC. | $128.39 | 2019-2022 | |
| Livanova USA, INC. | $125.25 | 2021-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Shire North American Group INC | $106.80 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $87.30 | 2019 | |
| Noven Therapeutics, LLC | $56.87 | 2023-2024 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $56.77 | 2022-2023 | Quviviq |
| Genentech, INC. | $39.95 | 2019 | |
| Owp Pharmaceuticals, INC. | $39.27 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $36.39 | 2021-2022 | |
| Alfasigma USA, INC. | $34.95 | 2021 | |
| Novo Nordisk INC | $26.30 | 2025 | Ozempic, Rybelsus |
| Rhodes Pharmaceuticals L.P. | $17.10 | 2019 | |
| Neuronetics, INC. | $16.55 | 2020 | |
| Biogen, INC. | $14.19 | 2025 | Zurzuvae |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Sweet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.